

EQA round: CSFK1/23 - Cerebrospinal Fluid Diagnostics

Deadline: 28.3.2023

Setup: groups - manufacturer of kit; minimal size of the groups n = 5

RoM = robust average

SD = standard deviation

CV = coefficient of variation

N_{tot} = total number of the resultsN_{out} = number of the results removed before calculation

AV = assigned value

CVP = consensus of all participants

U_{AV} = expanded uncertainty of the assigned value (k = 2)D_{max} = acceptable difference

LL = lower limit

UL = upper limit

N_{eva} = number of the results assessedN_{suc} = number of successful resultsS_{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL				
(398) Albumin	[mg/L]				46							46	46	100	
Sample K		654	43	6,5	46		CVP	654	15	23%	503	805	46	46	100
(60) Roche		632	29	4,6	17	0							17		
(149) Siemens (Dade, BN, Dimension)		666	35	5,2	7	0							7		
(162) Siemens (Atellica)		664	46	6,9	5	0							5		
(179) Siemens		636	38	5,9	6	0							6		
Other					11	0							11		
								1x 1, 4x 12, 2x 58, 3x 91, 1x 999							
(396) Glucose	[mmol/L]				45							45	44	98	
Sample K		4,69	0,13	2,7	45		CVP	4,69	0,047	18%	3,84	5,54	45	44	98
(46) Erba Lachema		4,36	0,44	10	5	0							5		
(58) Beckman Coulter (AU)		4,76	0,089	1,9	6	0							6		
(60) Roche		4,71	0,12	2,6	22	0							22		
Other					12	0							12		
								1x 0, 2x 1, 1x 49, 1x 75, 4x 162, 2x 179, 1x 188							
(401) IgA	[mg/L]				21							21	20	95	
Sample K		5,01	0,58	12	21		CVP	5,01	0,31	32%	3,4	6,62	21	20	95
(149) Siemens (Dade, BN, Dimension)		4,93	0,19	3,8	7	0							7		
Other					14	0							14		
								4x 12, 1x 58, 4x 91, 2x 162, 3x 179							
(399) IgG	[mg/L]				38							38	38	100	
Sample K		114	9	7,8	38		CVP	114	3,6	24%	86,6	142	38	38	100
(12) Beckman Coulter		119	8,9	7,5	6	0							6		
(60) Roche		109	4	3,7	13	0							13		
(149) Siemens (Dade, BN, Dimension)		121	13	10	7	0							7		
Other					12	0							12		
								1x 58, 4x 91, 3x 162, 4x 179							
(402) IgM	[mg/L]				24							24	23	96	
Sample K		3,6	0,48	13	24		CVP	3,6	0,24	31%	2,48	4,72	24	23	96
(91) Binding Site		3,11	0,28	9,1	5	0							5		
(149) Siemens (Dade, BN, Dimension)		3,6	0,15	4,1	7	0							7		
Other					12	0							12		
								4x 12, 1x 58, 2x 60, 2x 162, 3x 179							
(411) Intrathec. synt. IgA	[mg/L]				21							21	19	90	
Sample K												21	19	90	
(0) not specified		0	0		21	2	CVP	0	asym.	0	1	21			
(410) Intrathec. synt. IgG	[mg/L]				38							38	35	92	
Sample K												38	35	92	
(0) not specified		0	0		38	3	CVP	0	asym.	0	1	38			
(412) Intrathec. synt. IgM	[mg/L]				24							24	21	88	
Sample K												24	21	88	
(0) not specified		0	0		24	2	CVP	0	asym.	0	1	24			
(403) Lactate	[mmol/L]				46							46	45	98	
Sample K		1,61	0,079	4,9	46		CVP	1,61	0,028	20%	1,28	1,94	46	45	98
(58) Beckman Coulter (AU)		1,6	0	0	5	0							5		
(60) Roche		1,64	0,051	3,1	24	0							24		
Other					17	0							17		
								3x 1, 3x 49, 1x 75, 4x 162, 2x 179, 1x 187, 2x 188, 1x 998							
(413) Barrier permeability	[·10 ⁻³]				46							46	46	100	
Sample K												46	46	100	
(0) not specified		17,2	1,1	6,5	46	0	CVP	17,2	0,41	25%	12,9	21,5	46		